ALT

4.02

1.47% -0.06

Handel nachbörslich: 4.04 0.02 +0.50%

Altimmune Inc (ALT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$4.08

Offen:

$4.12

24-Stunden-Volumen:

2.99M

Relative Volume:

0.74

Marktkapitalisierung:

$419.46M

Einnahmen:

$409.00K

Nettoeinkommen (Verlust:

$-101.35M

KGV:

-2.4512

EPS:

-1.64

Netto-Cashflow:

$-71.49M

1W Leistung:

+14.53%

1M Leistung:

-27.17%

6M Leistung:

-15.19%

1J Leistung:

-46.04%

1-Tages-Spanne:

$3.985

$4.18

1-Wochen-Bereich:

$3.8601

$4.53

52-Wochen-Spanne:

$2.90

$7.73

Altimmune Inc Stock (ALT) Company Profile

Firmenname

Altimmune Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (621)

Telefon

(240) 654-1450

Adresse

910 CLOPPER ROAD, GAITHERSBURG, MD

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

ALT's Discussions on Twitter

Vergleichen Sie ALT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALT Altimmune Inc	4.02	425.72M	409.00K	-101.35M	-71.49M	-1.64
VRTX Vertex Pharmaceuticals Inc	463.86	119.17B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	796.55	84.19B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	398.29	52.77B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	788.49	48.98B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.97	36.31B	447.02M	-1.18B	-906.14M	-6.1812

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-10	Fortgesetzt	Goldman	Sell
2025-02-28	Eingeleitet	William Blair	Mkt Perform
2025-01-08	Eingeleitet	Stifel	Buy
2024-11-12	Eingeleitet	UBS	Buy
2024-04-29	Herabstufung	Guggenheim	Buy → Neutral
2024-01-24	Eingeleitet	Goldman	Neutral
2023-03-22	Herabstufung	Goldman	Buy → Neutral
2022-12-01	Eingeleitet	Goldman	Buy
2021-12-29	Fortgesetzt	Jefferies	Buy
2021-06-02	Eingeleitet	H.C. Wainwright	Buy
2021-02-11	Eingeleitet	Guggenheim	Buy
2020-12-14	Eingeleitet	Jefferies	Buy
2020-11-12	Bestätigt	B. Riley Securities	Buy
2020-09-25	Eingeleitet	B. Riley FBR	Buy
2020-08-14	Eingeleitet	Evercore ISI	Outperform
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-07-28	Eingeleitet	JMP Securities	Mkt Outperform
2020-02-24	Fortgesetzt	ROTH Capital	Buy
2019-07-19	Eingeleitet	ROTH Capital	Buy
2017-10-09	Eingeleitet	Piper Jaffray	Overweight

Alle ansehen

Altimmune Inc Aktie (ALT) Neueste Nachrichten

Jan 08, 2026

Altimmune (ALT) Is Up 13.0% After FDA Breakthrough Tag For Pemvidutide In MASHHas The Bull Case Changed? - Yahoo Finance

Jan 08, 2026

Published on: 2026-01-09 03:53:26 - ulpravda.ru

Jan 08, 2026

Will Altimmune Inc. stock split attract more investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - ulpravda.ru

Jan 08, 2026

Can Altimmune Inc. stock sustain free cash flow growthPrice Action & Low Risk Entry Point Guides - ulpravda.ru

Jan 08, 2026

Swing Trade: Why Altimmune Inc. stock remains on buy listsJuly 2025 Selloffs & Smart Allocation Stock Reports - ulpravda.ru

Jan 08, 2026

Jan 07, 2026

Altimmune (ALT) Is Up 16.1% After FDA Breakthrough Nod For AI-Enhanced MASH Drug Trial – Has The Bull Case Changed? - simplywall.st

Jan 07, 2026

ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - The Globe and Mail

Jan 07, 2026

Jan 06, 2026

Altimmune gains on FDA breakthrough designation for MASH therapy - MSN

Jan 06, 2026

Jan 05, 2026

Altimmune’s Surprising Stock Surge: What’s Behind It? - StocksToTrade

Jan 05, 2026

Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga

Jan 05, 2026

Altimmune shares rally after FDA awards breakthrough status to pemvidutide - MSN

Jan 05, 2026

Why Did Mobileye Stock Surge 8% Pre-Market Today? - Stocktwits

Jan 05, 2026

Altimmune (ALT) Surges on FDA Breakthrough Therapy Designation f - GuruFocus

Jan 05, 2026

Altimmune Receives FDA Breakthrough Therapy Designation For Pemvidutide In Mash - TradingView — Track All Markets

Jan 05, 2026

Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ) - Seeking Alpha

Jan 05, 2026

FDA grants breakthrough therapy status to Altimmune’s MASH drug By Investing.com - Investing.com Australia

Jan 05, 2026

Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug - TradingView — Track All Markets

Jan 05, 2026

Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Quiver Quantitative

Jan 05, 2026

Altimmune stock soars after FDA grants Breakthrough Therapy status By Investing.com - Investing.com Canada

Jan 05, 2026

Altimmune stock soars after FDA grants Breakthrough Therapy status - Investing.com

Jan 05, 2026

FDA flags new liver disease drug for faster review after promising early data - Stock Titan

Jan 05, 2026

Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug - Stocktwits

Jan 05, 2026

Dec 30, 2025

How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN

Dec 30, 2025

Dec 29, 2025

3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail

Dec 29, 2025

Dec 28, 2025

Jerome Durso Buys Handful Of Shares In Altimmune - Yahoo Finance

Dec 28, 2025

Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares - simplywall.st

Dec 28, 2025

Dec 27, 2025

Altimmune, Pure Storage, Globalstar, Cipher Mining, AutoZone Shake-Up - TipRanks

Dec 27, 2025

Dec 26, 2025

Altimmune announces CEO transition - MSN

Dec 26, 2025

Dec 25, 2025

Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus

Dec 25, 2025

Dec 24, 2025

Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN

Dec 24, 2025

Dec 23, 2025

Insider Buying: John Gill Acquires 12,500 Shares of Altimmune In - GuruFocus

Dec 23, 2025

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha

Dec 23, 2025

John Gill Acquires 12,500 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat

Dec 23, 2025

Altimmune Director John Gill Acquires 12,500 Shares - TradingView — Track All Markets

Dec 23, 2025

Altimmune stock soars over 10% premarket on positive mid-stage data for liver disease treatment drug - MSN

Dec 23, 2025

Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 23, 2025

Dec 22, 2025

Insider Buying: Jerome Durso Acquires 12,500 Shares of Altimmune Inc (ALT) - GuruFocus

Dec 22, 2025

Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Purchases 12,500 Shares - MarketBeat

Dec 22, 2025

Altimmune’s 48-Week MASH Data Still Leave Doubts On Fibrosis Benefit - Citeline News & Insights

Dec 22, 2025

Altimmune Director Jerome Benedict Durso Acquires 12,500 Shares - TradingView — Track All Markets

Dec 22, 2025

Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates - Seeking Alpha

Dec 22, 2025

Dec 21, 2025

Can Altimmune Inc. stock hit analyst price targetsJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - Улправда

Dec 21, 2025

Dec 20, 2025

How Altimmune Inc. stock compares to market leadersPortfolio Risk Report & Weekly Setup with High ROI Potential - Улправда

Dec 20, 2025

Will Altimmune Inc. stock benefit from upcoming earnings reports2025 Price Targets & Community Consensus Trade Signals - Улправда

Dec 20, 2025

Dec 19, 2025